

Pierre-François Laterre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/341058/publications.pdf>

Version: 2024-02-01

90
papers

12,047
citations

109321

35
h-index

46799

89
g-index

91
all docs

91
docs citations

91
times ranked

8106
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. <i>EBioMedicine</i> , 2022, 77, 103893.	6.1	48
2	Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial. <i>Journal of Critical Care</i> , 2022, 70, 154029.	2.2	2
3	Performance of the Cepheid Methicillin-Resistant <i>Staphylococcus aureus</i> / <i>S. aureus</i> Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for <i>S. aureus</i> Screening during the Phase 2 Double-Blind SAATELLITE Study. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	3.9	1
4	Acute Effects of Sitting Out of Bed and Exercise on Lung Aeration and Oxygenation in Critically Ill Subjects. <i>Respiratory Care</i> , 2021, 66, 253-262.	1.6	7
5	Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 149-157.	3.6	26
6	Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. <i>Critical Care</i> , 2021, 25, 61.	5.8	25
7	Prone Positioning in Spontaneously Breathing Subjects With Moderate or Severe ARDS During Invasive Ventilation. <i>Respiratory Care</i> , 2021, 66, 724-732.	1.6	3
8	Serum uric acid, disease severity and outcomes in COVID-19. <i>Critical Care</i> , 2021, 25, 212.	5.8	22
9	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. <i>Microorganisms</i> , 2021, 9, 1543.	3.6	23
10	Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e042921.	1.9	12
11	COVID-19: an "extraterrestrial" disease?. <i>International Journal of Infectious Diseases</i> , 2021, 110, 155-159.	3.3	3
12	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	2.9	46
13	Bioactive Adrenomedullin, Organ Support Therapies, and Survival in the Critically Ill. <i>Critical Care Medicine</i> , 2020, 48, 49-55.	0.9	13
14	A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit. <i>BMC Pulmonary Medicine</i> , 2020, 20, 309.	2.0	10
15	SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. <i>Kidney International</i> , 2020, 98, 1296-1307.	5.2	173
16	New Agents in Development for Sepsis: Any Reason for Hope?. <i>Drugs</i> , 2020, 80, 1751-1761.	10.9	23
17	A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol. <i>BMC Pulmonary Medicine</i> , 2020, 20, 317.	2.0	12
18	Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial. <i>Intensive Care Medicine</i> , 2020, 46, 1425-1437.	8.2	38

#	ARTICLE	IF	CITATIONS
19	The INHALE trial: multiple reasons for a negative result. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 778-779.	9.1	12
20	The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients. <i>Critical Care</i> , 2020, 24, 289.	5.8	57
21	Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 822-829.	5.6	31
22	The IASIS, INHALE and VAPORISE trials. Reasons for a triple failure: Study design, aminoglycosides dosing and technique of nebulisation. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 179-183.	1.4	11
23	Immunotherapies for COVID-19: lessons learned from sepsis. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 946-949.	10.7	111
24	Selepressin for Patients With Septic Shock—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 667.	7.4	1
25	Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1476.	7.4	107
26	Should we continue to test soluble thrombomodulin, or other systemic anticoagulants, as a life-saving therapy for sepsis-induced coagulopathy?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2019, 38, 419-421.	1.4	1
27	Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1419-1431.	2.3	9
28	CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 620-630.	9.1	44
29	Passive leg cycling and electrical stimulation cannot preserve strength in sepsis. <i>Critical Care</i> , 2019, 23, 37.	5.8	1
30	A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). <i>BMJ Open</i> , 2019, 9, e024475.	1.9	37
31	2160. Performance of the Cepheid Rapid PCR Test for Patient Screening and Association with Efficacy of Suvratouxumab, A Novel Anti-Staphylococcus aureus Monoclonal Antibody, During the Phase 2 SAATELLITE study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S733-S733.	0.9	2
32	One-Year Prognosis of Kidney Injury at Discharge From the ICU: A Multicenter Observational Study. <i>Critical Care Medicine</i> , 2019, 47, e953-e961.	0.9	21
33	Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1459-1461.	3.0	2
34	Open Lung Biopsy in Nonresolving Acute Respiratory Distress Syndrome Commonly Identifies Corticosteroid-Sensitive Pathologies, Associated With Better Outcome*. <i>Critical Care Medicine</i> , 2018, 46, 907-914.	0.9	21
35	Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock—Adaptive Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2018, 15, 250-257.	3.2	31
36	Hepatorenal syndrome: the clinical impact of vasoactive therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 173-188.	3.0	16

#	ARTICLE	IF	CITATIONS
37	Neutrophil-to-Lymphocyte Ratio Predicts Death in Acute-on-Chronic Liver Failure Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study. <i>Shock</i> , 2018, 49, 385-392.	2.1	40
38	Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study. <i>Kidney International Reports</i> , 2018, 3, 1424-1433.	0.8	53
39	Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. <i>Critical Care</i> , 2018, 22, 354.	5.8	75
40	Pattern of Paracetamol Poisoning: Influence on Outcome and Complications. <i>Toxics</i> , 2018, 6, 58.	3.7	10
41	Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by <i>Staphylococcus aureus</i> : first-in-human trial. <i>Intensive Care Medicine</i> , 2018, 44, 1787-1796.	8.2	57
42	Impact of Very Early Physical Therapy During Septic Shock on Skeletal Muscle: A Randomized Controlled Trial. <i>Critical Care Medicine</i> , 2018, 46, 1436-1443.	0.9	74
43	Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study. <i>Critical Care</i> , 2018, 22, 8.	5.8	123
44	A randomized placebo-controlled phase II study of a <i>Pseudomonas</i> vaccine in ventilated ICU patients. <i>Critical Care</i> , 2017, 21, 22.	5.8	77
45	SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study. <i>Pharmaceutical Research</i> , 2017, 34, 290-300.	3.5	59
46	Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference. <i>Annals of Intensive Care</i> , 2017, 7, 49.	4.6	100
47	Aerosol Delivery with Two Nebulizers Through High-Flow Nasal Cannula: A Randomized Cross-Over Single-Photon Emission Computed Tomography-Computed Tomography Study. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017, 30, 349-358.	1.4	44
48	Epidural analgesia in critically ill patients with acute pancreatitis: the multicentre randomised controlled EPIPAN study protocol. <i>BMJ Open</i> , 2017, 7, e015280.	1.9	32
49	Aerosol delivery during invasive mechanical ventilation: a systematic review. <i>Critical Care</i> , 2017, 21, 264.	5.8	47
50	Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. <i>Critical Care</i> , 2017, 21, 213.	5.8	93
51	Perspective on optimizing clinical trials in critical care: how to puzzle out recurrent failures. <i>Journal of Intensive Care</i> , 2016, 4, 67.	2.9	12
52	Teamwork enables high level of early mobilization in critically ill patients. <i>Annals of Intensive Care</i> , 2016, 6, 80.	4.6	61
53	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). <i>World Journal of Emergency Surgery</i> , 2016, 11, 33.	5.0	130
54	Changes in cardiac arrest patients' temperature management after the 2013 'TTM' trial: results from an international survey. <i>Annals of Intensive Care</i> , 2016, 6, 4.	4.6	71

#	ARTICLE	IF	CITATIONS
55	Breakthrough in cardiac arrest: reports from the 4th Paris International Conference. <i>Annals of Intensive Care</i> , 2015, 5, 22.	4.6	27
56	Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2015, 60, 997-1006.	5.8	64
57	Prone positioning induced hepatic necrosis after liver transplantation. <i>Intensive Care Medicine</i> , 2015, 41, 1833-1833.	8.2	2
58	Early hyperlactatemia predicts pancreatic fistula after surgery. <i>BMC Anesthesiology</i> , 2015, 15, 109.	1.8	12
59	Influence of Inspiratory Flow Pattern and Nebulizer Position on Aerosol Delivery with a Vibrating-Mesh Nebulizer During Invasive Mechanical Ventilation: An <i>in Vitro</i> Analysis. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 229-236.	1.4	36
60	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 891-898.	3.0	71
61	Myeloid-related protein-8/14 facilitates bacterial growth during pneumococcal pneumonia. <i>Thorax</i> , 2014, 69, 1034-1042.	5.6	36
62	Tracking the foreign body, a rare cause of hepatic abscess. <i>BMC Gastroenterology</i> , 2014, 14, 167.	2.0	18
63	Current practices and barriers impairing physicians' and nurses' adherence to analgo-sedation recommendations in the intensive care unit - a national survey. <i>Critical Care</i> , 2014, 18, 655.	5.8	55
64	Energy expenditure in the critically ill performing early physical therapy. <i>Intensive Care Medicine</i> , 2014, 40, 548-555.	8.2	52
65	What stops us from following sedation recommendations in intensive care units? A multicentric qualitative study. <i>Journal of Critical Care</i> , 2014, 29, 291-297.	2.2	20
66	NAVA enhances tidal volume and diaphragmatic electro-myographic activity matching: a Range90 analysis of supply and demand. <i>Journal of Clinical Monitoring and Computing</i> , 2013, 27, 61-70.	1.6	25
67	Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. <i>Critical Care</i> , 2012, 16, R14.	5.8	155
68	Electrical Vagus Nerve Stimulation and Nicotine Effects in Peritonitis-Induced Acute Lung Injury in Rats. <i>Inflammation</i> , 2011, 34, 29-35.	3.8	42
69	Neurally adjusted ventilatory assist improves patient-ventilator interaction. <i>Intensive Care Medicine</i> , 2011, 37, 263-271.	8.2	199
70	Delayed colopericardial fistula and pyopneumopericardium. <i>Intensive Care Medicine</i> , 2010, 36, 557-558.	8.2	2
71	A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. <i>Critical Care</i> , 2009, 13, R36.	5.8	33
72	Therapeutic dose of acetaminophen may be able to induce fulminant hepatitis in the presence of risk factors of hepatotoxicity. Report of two cases and short review. <i>British Journal of Anaesthesia</i> , 2009, 103, .	3.4	0

#	ARTICLE	IF	CITATIONS
73	Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. <i>Critical Care</i> , 2008, 12, R117.	5.8	9
74	Severe community acquired pneumonia update: mortality, mechanisms and medical intervention. <i>Critical Care</i> , 2008, 12, S1.	5.8	9
75	Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition. <i>Critical Care</i> , 2008, 12, S4.	5.8	13
76	Progress in medical management of intra-abdominal infection. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 393-398.	3.1	12
77	ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation*. <i>Critical Care Medicine</i> , 2007, 35, 1457-1463.	0.9	38
78	Clinical trials in severe sepsis with drotrecogin alfa (activated). <i>Critical Care</i> , 2007, 11, S5.	5.8	29
79	International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. <i>Journal of Critical Care</i> , 2007, 22, 142-152.	2.2	20
80	Pharmacological Inhibition of Tissue Factor. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 071-076.	2.7	13
81	Compartmentalization of the protease-antiprotease balance in early severe acute pancreatitis. <i>Suizo</i> , 2006, 21, 99-101.	0.1	0
82	Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial *. <i>Critical Care Medicine</i> , 2004, 32, 2207-2218.	0.9	95
83	Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. <i>Intensive Care Medicine</i> , 2003, 29, 894-903.	8.2	166
84	Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification. <i>Critical Care</i> , 2003, 7, 445.	5.8	20
85	Anticoagulant therapy in acute lung injury. <i>Critical Care Medicine</i> , 2003, 31, S329-S336.	0.9	87
86	Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. <i>New England Journal of Medicine</i> , 2001, 344, 699-709.	27.0	8,411
87	Recurrent postinfantile syncytial giant cell hepatitis after orthotopic liver transplantation. <i>Transplant International</i> , 1998, 11, 320-322.	1.6	13
88	Recurrent postinfantile syncytial giant cell hepatitis after orthotopic liver transplantation. <i>Transplant International</i> , 1998, 11, 320-322.	1.6	6
89	Adult liver transplantation and abnormalities of splanchnic veins: experience in 53 patients. <i>Transplant International</i> , 1997, 10, 125-132.	1.6	71
90	Adult liver transplantation and abnormalities of splanchnic veins: experience in 53 patients. <i>Transplant International</i> , 1997, 10, 125-132.	1.6	25